Share price · OGN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
See what was announced around each unusual move
Research flags the days this stock moved far more than its sector fund, lists the news, filings and earnings dated around each one, and shows how much of its unusual movement fell on each asset's announcements.
Assets
(12 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | TNF-alpha | Inflammatory Bowel DiseasePsoriatic Arthritis Ulcerative Colitis, Crohn's Disease | |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | Schizophrenia | |
| Approved | TNF-alpha | Inflammatory Bowel Disease Ulcerative Colitis, Crohn's Disease | |
mometasone furoate/formoterol fumarate(Dulera / Zenhale) | Approved | Glucocorticoid receptor; Beta-2 adrenergic receptorSmall molecule | Asthma |
| Approved | Cysteinyl leukotriene receptor 1 (CysLT1)Small molecule | Asthma | |
| Approved | —Small molecule | Migraine | |
| Approved | Aryl hydrocarbon receptor · Aryl Hydrocarbon Receptor AgonistSmall molecule | Atopic DermatitisPsoriasis | |
AtovastatinNo recent activity | Phase 3 | HMG-CoA reductaseSmall molecule | Atherosclerotic Cardiovascular Disease |
Ezetimibe(Zetia) | Phase 3 | Dietary Cholesterol Absorption Inhibitor · NPC1L1Small molecule | Atherosclerotic Cardiovascular Disease |
MK0653A, ezetimibe (+) simvastatinNo recent activity | Phase 3 | HMG-CoA reductase / NPC1L1Small molecule | Atherosclerotic Cardiovascular Disease |
| Phase 3 | HMG-CoA reductase (rosuvastatin component) + NPC1L1 intestinal cholesterol transporter (ezetimibe component)Small molecule | Atherosclerotic Cardiovascular Disease | |
| Preclinical / Unstaged | HMG-CoA reductase / NPC1L1Small molecule | Atherosclerotic Cardiovascular Disease |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Unlock insider transactions
Research includes SEC Form 4 insider transactions: filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Unlock institutional holders
Research includes quarterly SEC 13F institutional ownership: top holders, aggregate positions and quarter-over-quarter context.